IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | Material Management Information related to Judgment of Investment(COVID-19 예방 백신 AdCLD-CoV19-1 LP.8.1의 제2상 임상시험 계획 승인(IND) 신청 반려) | 2026-05-08 | |
| 9 | [Revised]New Facilities Investment, etc. | 2026-04-30 | |
| 8 | [Revised]Resolutions for Convocation of General Meeting of Shareholders(임시주주총회) | 2026-04-30 | |
| 7 | Extension of overheated short-selling issue designation (subject to extension of restriction on short-selling) | KOSDAQ STOCK MKT. | 2026-04-22 |
| 6 | Designation of overheated short-selling issues (applied by a restriction on short-selling) | KOSDAQ STOCK MKT. | 2026-04-21 |
| 5 | (Forewarning) Designation as Temporary Overheated Issue | KOSDAQ STOCK MKT. | 2026-04-20 |
| 4 | Advance notice for assignment of issue for abnormal rise | 2026-04-20 | |
| 3 | Resolutions for Convocation of General Meeting of Shareholders(임시주주총회) | 2026-04-06 | |
| 2 | Outcomes of Annual Meeting of Shareholders | 2026-03-31 | |
| 1 | [Revised]New Facilities Investment, etc. | 2026-03-30 |
